JaLCDOI 10.18926/AMO/53028
FullText URL 68_6_379.pdf
Author Doi, Shinichiro| Kimura, Shuhei| Morizane, Yuki| Hosogi, Mika| Hosokawa, Mio| Shiode, Yusuke| Kawata, Tetsuhiro| Kondo, Eisei| Shiraga, Fumio|
Abstract We report a case of POEMS syndrome in a 20-year-old patient diagnosed after visiting an eye clinic with a chief complaint of reduced visual acuity. A male university student aged 20 years was referred to our department complaining of blurred vision in both eyes that had persisted for 1 month. He also noted headache, nausea, and paresthesia in the lower extremities around the same time. The visual acuity of his right and left eye was 20/40 and 20/20, respectively. Optic disc edema and serous retinal detachment were present. Brain magnetic resonance imaging showed no intracranial abnormalities, while elevated cerebrospinal fluid pressure, reduced nerve conduction velocity in both lower extremities, hepatosplenomegaly, M proteinemia, high blood VEGF levels, osteoblastic and osteolytic changes in the spine, and atypical plasma cells in bone lesions were noted. From the above findings, the patient was diagnosed with POEMS syndrome. He received high-dose dexamethasone, thalidomide, and radiotherapy on the sacral mass, followed by high-dose melphalan with autologous stem-cell support, and showed subsequent systemic and ophthalmologic improvement. Here, we report the youngest case ever of POEMS syndrome with ocular manifestation. If patients have optic disc edema in both eyes with no intracranial space-occupying lesion, POEMS syndrome should be considered in differential diagnosis, regardless of age.
Keywords POEMS syndrome serous retinal detachment VEGF
Amo Type Case Report
Published Date 2014-12
Publication Title Acta Medica Okayama
Volume volume68
Issue issue6
Publisher Okayama University Medical School
Start Page 379
End Page 383
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 25519033
Web of Sience KeyUT 000346882200009
JaLCDOI 10.18926/AMO/55661
FullText URL 72_1_39.pdf
Author Hosogi, Mika| Morizane, Yuki| Shiode, Yusuke| Doi, Shinichiro| Kumase, Fumiaki| Kimura, Shuhei| Hosokawa, Mio| Hirano, Masayuki| Toshima, Shinji| Takahashi, Kosuke| Fujiwara, Atsushi| Shiraga, Fumio|
Abstract To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed. BCVA and CRT both improved significantly at 1 year compared with baseline (p<0.001). Sixteen eyes (45.7%) were included in the TAE to PRN group, while 19 eyes (54.3%) were included in the continued TAE group. BCVA in the TAE to PRN group was significantly better than that in the continued TAE group at 1 year (p=0.047). BCVA at baseline and macular BRVO were significant predictive factors for inclusion in the TAE to PRN group. TAE was effective for improving BCVA and CRT. The TAE to PRN group showed significantly better prognosis.
Keywords branch retinal vein occlusion macular edema anti-vascular endothelial growth factor ranibizumab treat-and-extend regimen
Amo Type Original Article
Published Date 2018-02
Publication Title Acta Medica Okayama
Volume volume72
Issue issue1
Publisher Okayama University Medical School
Start Page 39
End Page 45
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29463937
Web of Sience KeyUT 000426542800006
NAID 120006398861
JaLCDOI 10.18926/AMO/56175
FullText URL 72_4_379.pdf
Author Morizane-Hosokawa, Mio| Morizane, Yuki| Kimura, Shuhei| Shiode, Yusuke| Hirano, Masayuki| Doi, Shinichiro| Toshima, Shinji| Hosogi, Mika| Fujiwara, Atsushi| Shiraga, Fumio|
Abstract We conducted intravitreal aflibercept injections (IVAs) for 37 Japanese patients (28 males, 9 females, mean age 73.4 years) with polypoidal choroidal vasculopathy (PCV), with a treat-and-extend regimen (TER). We evaluated the impact of polyp regression after a loading dose (2-mg IVA 1×/month for 3 months) on the patients' 2-year treatment outcomes. Thirty-seven eyes were treated with IVA by a TER for 2 years. We divided the patients into 2 groups based on their polyp status after the loading dose: polyp regression (PR+) (n=19) and no polyp regression (PR−) (n=18). We compared the groups’ best-corrected visual acuity (BCVA), central retinal thickness (CRT), recurrence rate, total number of injections, and final treatment interval. Both the BCVA and CRT were significantly improved by the treatment in both groups, with no between-group difference in the amount of change (p=0.769). In the polyp regression (+) group, recurrence was significantly less common (p=0.03), the mean total number of injections was significantly lower (p=0.013), and the mean treatment interval was significantly longer (0.042). Regarding the 2-year outcomes for PCV, the eyes with post-loading-dose polyp regression demonstrated less frequent recurrence and required fewer numbers of injections compared to the eyes without polyp regression.
Keywords polypoidal choroidal vasculopathy aflibercept treat-and-extend regimen polyp regression
Amo Type Original Article
Published Date 2018-08
Publication Title Acta Medica Okayama
Volume volume72
Issue issue4
Publisher Okayama University Medical School
Start Page 379
End Page 385
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30140086